Biliary tract cancer
Showing 1 - 25 of >10,000
Observational Monocentric Study on Biliary Tract Cancer (BABEL)
Recruiting
- Biliary Tract Cancer
-
Roma, Rome, ItalyFondazione Policlinico Universitario Agostino Gemelli/IRCSS - UO
Jul 10, 2023
Advanced Biliary Tract Cancer Trial in Tianjin (Cadonilimab+Regorafenib+GC)
Not yet recruiting
- Advanced Biliary Tract Cancer
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Apr 7, 2023
Advanced Biliary Tract Cancer Trial (anlotinib+TQB2450+nab-paclitaxel+cisplatin)
Not yet recruiting
- Advanced Biliary Tract Cancer
- (no location specified)
Apr 2, 2023
Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)
Recruiting
- Advanced Biliary Tract Cancer
- Sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 22, 2023
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance Study -
Not yet recruiting
- Biliary Tract Cancer
- (no location specified)
Apr 26, 2023
Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)
Not yet recruiting
- Locally Advanced Biliary Tract Cancer
- Metastatic Biliary Tract Cancer
- Camrelizumab and Apatinib Plus GP
-
Guangzhou, Guangdong, ChinaCancer center of SunYat-sen University
Feb 15, 2023
Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)
Recruiting
- Biliary Tract Neoplasms
- Immunotherapy
- Durvalumab
- +2 more
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Jul 6, 2023
Biliary Tract Cancer, Immune Checkpoint Inhibitor, Predictive Cancer Model Trial in Beijing (Immune Checkpoint Inhibitors)
Recruiting
- Biliary Tract Cancer
- +2 more
- Immune Checkpoint Inhibitors
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Oct 5, 2023
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)
Not yet recruiting
- HER2-positive Colorectal Cancer
- HER2-positive Biliary Tract Cancer
- KN026
- +2 more
-
Beijing, State*, ChinaPeking University cancer hospital & institution
Aug 2, 2023
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary
Recruiting
- Biliary Tract Cancer
- Blood drawing
-
Guangzhou, Guangdong, China
- +1 more
Dec 28, 2022
Biliary Tract Tumors, Gallbladder Cancer, Cholangiocarcinoma Trial in Seoul (Durvalumab + Gem/Cis, Gem/Cis)
Active, not recruiting
- Biliary Tract Neoplasms
- +2 more
- Durvalumab + Gem/Cis
- Gem/Cis
-
Seoul, Korea, Republic ofAsan Medical Center
Jan 30, 2023
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer Trial in Seoul
Not yet recruiting
- HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System
Feb 19, 2023
LIver, Biliary tRAct and pancReatic Cancers
Recruiting
- Liver Cancer
- +2 more
- Blood drawing
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital, Zhejiang University School of Me
Nov 14, 2023
Resectable Biliary Tract Cancer Trial in Tianjin (Cisplatin, Gemcitabine, Nab-paclitaxel)
Recruiting
- Resectable Biliary Tract Cancer
- Cisplatin
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Nov 30, 2022
Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)
Recruiting
- Biliary Tract Cancer
- +2 more
-
Shanghai, ChinaZhongshan hospital, Fudan University
Aug 12, 2023
Multi-Platform Profiling of Resected Biliary Tract Cancer
Recruiting
- Biliary Tract Cancer
- +7 more
- Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
-
Chicago, Illinois
- +1 more
Jan 23, 2023
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer Trial in Seongnam-si (nab-paclitaxel plus gemcitabine-cisplatin)
Recruiting
- Biliary Tract Cancer
- +2 more
- nab-paclitaxel plus gemcitabine-cisplatin
-
Seongnam-si, Gyeonggi-do, Korea, Republic ofCHA Bundang Medical Center
Oct 27, 2022
Advanced Biliary Tract Cancer Trial in Changsha (IBI310, sintilimab)
Not yet recruiting
- Advanced Biliary Tract Cancer
-
Changsha, Hunan, ChinaHunan cancer Hospital
Dec 13, 2022
Postoperative Recurrence in Biliary Tract Cancers:A Multicenter
Recruiting
- Biliary Tract Cancer
- No intervention
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with NanJing Medical University
Feb 15, 2023
Biliary Tract Cancer Trial in Kaohsiung, Taichung (D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX)
Recruiting
- Biliary Tract Cancer
- D07001-softgel capsules + Xeloda (or TS-1)
- mFOLFOX
-
Kaohsiung, Taiwan
- +4 more
Dec 22, 2022
